statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a...

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

FDA approves Cerus' 12-month shelf life for INTERCEPT platelet processing sets

Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of...

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets Doubling Previous Shelf Life

Investors eyeing a purchase of Cerus Corp. (CERS) shares, but tentative about paying the going market price of 1.93/share, might benefit from considering selling puts among the alternative...

Commit To Purchase Cerus At $1, Earn 32.6% Annualized Using Options

Cathie Wood's ARK Investment bought 193K shares of Cerus today

Cathie Wood's ARK Investment bought 278K shares of Cerus today

Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to...

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Cerus (CERS Research Report), with a price target of $5.00. Jo...

Cerus's Strong Q4 Performance and Positive 2024 Outlook Prompt 'Buy' Rating

Cerus Co. (NASDAQ:CERS  Get Free Report) CEO William Mariner Greenman sold 62,315 shares of Cerus stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price...

Insider Selling: Cerus Co. (NASDAQ:CERS) CEO Sells $128,368.90 in Stock

Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Volume	114,896.00
52-Wk High	$3.08
52-Wk Low	$1.21

CERS Cerus Corp.

About

Feed

News

Sentiment

Earnings

Fundamentals